Market Intelligence

Specialist intelligence
for consumer healthcare.

Ingredient trends, regulatory signals, competitive moves, and white space analysis across three categories of consumer healthcare. Updated monthly. Prepared by Brendan Walsh, Principal.

Three verticals live  ·  Monthly cadence

July 2026
01
Dietary Supplements

Ingredient-level tracking across five high-growth segments. Evidence quality, velocity, and regulatory risk mapped monthly.

Segments tracked

Vitamins & minerals  ·  Gut health  ·  Nootropics  ·  Beauty & longevity  ·  Women's health

View Supplement Intelligence →
02
OTC & Consumer Health

Over-the-counter category tracking across four therapeutic segments. Claim landscape, reformulation signals, Rx-to-OTC pipeline, and competitive brand moves.

Segments tracked

Pain management  ·  Respiratory health  ·  Gastrointestinal  ·  Dermatological

View OTC Intelligence →
03
Oral Health

Ingredient and technology tracking across five oral health segments. Clinical evidence, regulatory positioning, and branded ingredient moves mapped monthly.

Segments tracked

Caries prevention  ·  Periodontal care  ·  Aesthetic / cosmetic  ·  Denture care  ·  Specialised

View Oral Health Intelligence →

Latest signals — Edition 04  ·  July 2026

Dietary Supplements
FDA reverses course, confirms NMN is a lawful dietary ingredient again after a three-year disruption
Xlear v. FTC suit seeks to flip the burden of proof on supplement health claims, testing the Loper Bright precedent
Live it Up Super Greens Salmonella outbreak reopens: 119 illnesses, 32 hospitalizations across 36 states
OTC & Consumer Health
FDA finalizes bemotrizinol, the first new US sunscreen active in 20 years; market entry August 9, 2026
OMUFA II locks in FDA monograph program funding through FY2030, five-year certainty for sponsors
Oral phenylephrine final order still unpublished as the 2026 cold season approaches
Oral Health
Hydroxyapatite gains clinical legitimacy in active US trials, but anti-caries claims remain unapproved domestically
PAP+ becomes the default peroxide alternative in premium whitening, led by Hismile and other DTC brands
Peri-implantitis reframed as a systemic inflammatory condition as implant volumes and maintenance demand grow

How the intelligence is produced

01
Primary source monitoring

FDA and FTC databases, ClinicalTrials.gov, PubMed, and regulatory dockets tracked monthly. Retail velocity from SPINS and trade press. No aggregator dependency.

02
Consultant framing

Every signal is translated into a concrete implication. Not what happened — what a brand, investor, or advisory client should do with it. Three decades of category experience in every observation.

03
Transparent data quality

Intelligence is directional secondary-source analysis unless otherwise noted. Where SPINS or primary data underpins a finding, it is cited. I distinguish signal from noise — and say so when I cannot tell the difference.

Three verticals. Monthly cadence. Built for the practitioner who needs to know what's moving — and why it matters.

Access the Intelligence Platform →
Ballymote Group Intelligence
Request access to continue

This intelligence is prepared for a select audience. Submit your details — Brendan will follow up directly.

✓
Access granted.

Unlocking now. Brendan will be in touch shortly.

Already have access? Contact Brendan directly.